A Phase II Study of Intravenous DX-8951f [exatecan] Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Exatecan (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 15 May 2012 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 10 Sep 2005 New trial record.